Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOE901-U300 versus Lantus in older adults with type 2 diabetes
2014-002399-10Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c from baseline. Started Nov 2014; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-002399-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002399-10.